In this report, we have shown that lowering expression of MMR factors identified as HD-onset modifiers to levels regularly achieved by current therapeutic modalities was sufficient to slow the pathogenic expansion of the HTT CAG repeat tract. This evidence concerns the gene MRC1 and Huntington disease.